论文部分内容阅读
肺癌的发病率及病死率占恶性肿瘤的首位,非小细胞肺癌(NSCLC)约占肺癌患者总数的80%,其中一半患者年龄60岁以上。目前多西他赛单药治疗晚期NSCLC治疗的标准二线药物,可延长患者总生存时间,但不良反应较大。目前多项研究证实,培美曲赛二线治疗晚期NSCLC疗效与多西他赛相似,且不良反应很小。本文总结了我院呼吸科2007-01-2010-01使用培美曲赛单药治疗NSCLC患者23例,并对疗效进行了总
The incidence and mortality of lung cancer make up the top of malignant tumors. Non-small cell lung cancer (NSCLC) accounts for about 80% of the total number of lung cancer patients, and half of them are over 60 years of age. Currently docetaxel monotherapy in the treatment of advanced second-line NSCLC treatment of second-line drugs, can extend the overall survival time, but adverse reactions. A number of studies have confirmed that pemetrexed second-line treatment of advanced NSCLC efficacy and docetaxel similar, and adverse reactions are small. This article summarizes the respiratory department of our hospital 2007-01-2010-01 Pemetrexed monotherapy for the treatment of 23 patients with NSCLC, and the total effect of the total